/
Oncology
Glioblastoma
176
Pipeline Programs↗
227
Active Trials↗
111
Companies Involved↗
Glioblastoma is a highly competitive landscape with 176 programs across 111 companies. The most active players are Novartis, Beijing Pearl Biotechnology Limited Liability Company, Laminar Pharmaceuticals. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 158
Phase 280
Phase 319
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
120 of 153 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 153 classified programs, each share of the total. Modality classified for 96% of 176 pipeline programs.
Analysis
Trial Status
639
clinical trials
Completed230 · 36%
Recruiting108 · 17%
Active, not recruiting84 · 13%
Terminated79 · 12%
Unknown status58 · 9%
Not yet recruiting35 · 5%
Other45 · 7%
Clinical Trials
Trial Activity
639 trials
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM)
Recruiting·—·Phase 1·NCT06132438·26 enrolled
A Phase 0/2 Study of BGB-58067, an MTA Cooperative PRMT5 Inhibitor, in Newly Diagnosed Glioblastoma Patients With Methylthioadenosine Phosphorylase (MTAP) Deleted Tumors Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD)-Triggered Expansion Cohorts
Recruiting·—·Phase 1·NCT07485049·78 enrolled
Page 1 of 43
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)